Shop by goal

Popular compounds

GHK-Cu Copper Peptide

Retatrutide

Research resources

Semaglutide Research Guide: STEP, SELECT and 2025–26 Trial Results, Mechanism and Oral vs Injectable

In short: Semaglutide is a 31-amino-acid synthetic peptide and a selective GLP-1 receptor agonist from Novo Nordisk. Licensed medicines include Ozempic, Wegovy and Rybelsus. STEP-1 reported a −14.9% mean change in body weight at week 68 with the 2.4 mg arm in its study population, and STEP UP (2025) reported −18.7% at week 72 with a 7.2 mg arm. New-U lists research-grade lyophilised semaglutide with its Certificate of Analysis published online, research use only.

Key facts

31-amino-acid GLP-1 analogue; half-life about 7 days (albumin binding via C18 fatty di-acid).

Single GLP-1 agonist; no GIP or glucagon receptor activity.

Evidence base: SUSTAIN (diabetes), STEP (weight management), SELECT (cardiovascular outcomes), FLOW (kidney outcomes), ESSENCE (MASH liver histology); the evoke trials in early Alzheimer’s disease were negative.

Licensed medicines and research-grade reference peptide are separate supply categories.

New-U sells the research reagent only: no human-use claims or dosing guidance.

Semaglutide turned “GLP-1” into a household acronym. It draws roughly 550,000 monthly Google searches in the United States alone . It sits just behind tirzepatide in the incretin search landscape. Head-to-head trials often use it as the active comparator because it is the established single-agonist standard. This guide covers the molecule, the STEP and SUSTAIN results, injectable versus oral forms, and how research-grade Semaglutide sits on the New-U catalogue. For the Ozempic question, see Is Ozempic a Peptide?. For single-versus-dual comparison, see Semaglutide vs Tirzepatide.

Plain-English summary. Semaglutide is an approved medicine in the United States, the United Kingdom and many other jurisdictions when supplied through licensed channels as Ozempic, Wegovy or Rybelsus. Research-grade semaglutide, sold as a lyophilised reference peptide for laboratory use, is a separate non-medicine category. New-U sells only the research reagent, not the medicine, with no human-use claims, no dosing guidance and no therapeutic protocol. This page is general information, not legal or medical advice.

What semaglutide actually is

Semaglutide is a 31-amino-acid analogue of human glucagon-like peptide-1 (GLP-1). It uses the GLP-1(7–37) backbone with three engineering changes: an Aib substitution at position 8 to block DPP-4 cleavage, an arginine at position 34 , and a C18 fatty di-acid on Lys26 via a γ-Glu-2xOEG linker. The fatty di-acid drives reversible albumin binding. That binding extends half-life from native GLP-1’s ~2 minutes to semaglutide’s ~7 days.

The result is a selective GLP-1 receptor agonist with no off-target GIP or glucagon activity. Pharmacokinetics support once-weekly subcutaneous dosing in the licensed setting. The full mechanism is reviewed in the StatPearls semaglutide chapter.

Mechanism of action, in plain English

GLP-1 receptor agonism produces a cluster of overlapping effects:

Slowed gastric emptying. Food residence time in the stomach increases, prolonging satiety signalling.

Central signalling. GLP-1 receptors in the hypothalamus and brainstem are investigated in relation to energy-intake and food-reward endpoints measured in published studies.

Glucose-dependent insulin secretion. β-cell response to a glucose load is amplified only when glucose is elevated. That glucose dependence is why hypoglycaemia is reported far less often with GLP-1 agonists than with insulin or sulfonylureas.

Glucagon suppression in a glucose-dependent manner, lowering hepatic glucose production.

What semaglutide does not do, in contrast to tirzepatide and retatrutide, is activate the GIP or glucagon receptors. That is the single mechanistic line separating it from the dual and triple agonists.

The clinical evidence: STEP, SUSTAIN, SELECT and later trials

Semaglutide has the deepest Phase 3 evidence base of any peptide in the incretin class:

SUSTAIN (type-2 diabetes, 10 trials). Reported HbA1c reductions of ~1.5–1.8% from baseline at the 1.0 mg weekly dose, superior to comparators across the programme including sitagliptin (SUSTAIN-2), exenatide (SUSTAIN-3) and insulin glargine (SUSTAIN-4).

STEP (chronic weight management). STEP-1 (NEJM, 2021; PMID 33567185) reported a mean change in body weight of −14.9% at week 68 in the 2.4 mg arm, vs −2.4% for placebo, in 1,961 adults with overweight or obesity without diabetes. Its primary estimand assessed the effect regardless of treatment discontinuation or rescue interventions. The 2.4 mg dose became the basis for the Wegovy approval.

STEP UP (higher maintenance dose). STEP UP (Wharton et al., Lancet Diabetes Endocrinol 2025; PMID 40961952) randomised 1,407 adults with obesity without diabetes to 7.2 mg, 2.4 mg or placebo for 72 weeks. Mean change in body weight was −18.7% with 7.2 mg vs −3.9% with placebo (treatment-policy estimand) and vs −15.6% with 2.4 mg. Dysaesthesia was reported more often with 7.2 mg (22.9% vs 6.0% with 2.4 mg). In the companion STEP UP T2D trial (Lingvay et al., 2025; PMID 40961953) in adults with obesity and type 2 diabetes, the 7.2 mg arm reported −13.2% vs −3.9% with placebo.

SELECT (cardiovascular outcomes). It showed a significant reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease. It was the first GLP-1 outcomes trial in a non-diabetic population, and it underpinned the 2024 cardiovascular-protection label expansion. In 17,604 participants a primary endpoint event occurred in 6.5% with semaglutide vs 8.0% with placebo (hazard ratio 0.80; Lincoff et al., NEJM 2023; PMID 37952131).

FLOW (kidney outcomes). In 3,533 participants with type 2 diabetes and chronic kidney disease, the risk of major kidney-disease events was 24% lower with semaglutide 1.0 mg than with placebo (hazard ratio 0.76; Perkovic et al., NEJM 2024; PMID 38785209).

ESSENCE (MASH). In the planned week-72 interim analysis of this phase 3 trial (Sanyal et al., NEJM 2025; PMID 40305708), in 800 patients with biopsy-defined metabolic dysfunction-associated steatohepatitis and fibrosis stage 2 or 3, resolution of steatohepatitis without worsening of fibrosis was reported in 62.9% with semaglutide 2.4 mg vs 34.3% with placebo, and reduction in fibrosis without worsening of steatohepatitis in 36.8% vs 22.4%.

evoke and evoke+ (early Alzheimer’s disease). These two phase 3 trials of oral semaglutide in 3,808 participants with amyloid-confirmed early Alzheimer’s disease were negative : semaglutide did not slow clinical progression on the primary endpoint (change in CDR-SB to week 104) compared with placebo in either trial, and both trials were discontinued (Cummings et al., Lancet 2026; PMID 41865758).

Injectable vs oral semaglutide

Semaglutide has an approved oral formulation (Rybelsus) as well as the injectable one. The molecule is the same; the formulation differs. Rybelsus co-formulates semaglutide with SNAC (sodium N-(8-(2-hydroxybenzoyl) amino) caprylate). SNAC briefly raises gastric pH and loosens the mucosal barrier so the peptide can cross.

Oral bioavailability is around 0.4–1.0% . That is why labelled oral dose strengths are much higher than injectable ones. Licensed oral labelling also requires specific empty-stomach timing for absorption. Those details belong to the medicine label, not to research-compound handling.

Oral semaglutide has also been studied in obesity. In OASIS 4 (Wharton et al., NEJM 2025; PMID 40934115), once-daily oral semaglutide 25 mg in 307 randomised adults with overweight or obesity without diabetes reported a mean change in body weight of −13.6% at week 64 vs −2.2% with placebo. In SOUL (McGuire et al., NEJM 2025; PMID 40162642), oral semaglutide in type 2 diabetes with cardiovascular or kidney disease reported a lower risk of major adverse cardiovascular events than placebo (hazard ratio 0.86).

Semaglutide vs tirzepatide vs retatrutide

The full incretin landscape:

Compound Receptor profile Amino acids Half-life Status Semaglutide Semaglutide GLP-1 only 31 ~7 days Approved (Ozempic, Wegovy, Rybelsus) Tirzepatide Tirzepatide GLP-1 + GIP 39 ~5 days Approved (Mounjaro, Zepbound) Retatrutide Retatrutide GLP-1 + GIP + glucagon 39 ~6 days Phase 3, no approval

In the SURMOUNT-5 head-to-head (Aronne et al., NEJM 2025; PMID 40353578), an open-label trial in 751 adults with obesity without type 2 diabetes at maximum tolerated doses, the least-squares mean change in body weight at week 72 was −20.2% with tirzepatide vs −13.7% with semaglutide. Semaglutide has the longer published outcomes record, including SELECT in a population without diabetes.

Semaglutide as a research compound

On the New-U catalogue, the research-grade reference peptide is listed as Semaglutide . It shares the same 31-amino-acid sequence and selective GLP-1 mechanism described above. Here it is supplied as a research compound beside our wider incretin reference range (semaglutide, tirzepatide and retatrutide), not as a licensed medicine.

>99% HPLC purity , independently verified by Janoshik Analytics and Freedom Diagnostics , with the Certificate of Analysis for the tested sample published online.

Sealed 10-vial packs , lyophilised, multiple mg/vial tiers.

Tracked worldwide delivery , with flat-rate UK / US / EU options.

No human-use, dosing, therapeutic or weight-loss claims anywhere on the listing.

Operated by a Wyoming-registered distributor - a verifiable legal entity, not an anonymous storefront.

How to verify semaglutide purity

For a 31-amino-acid lipidated peptide, the purity questions are:

HPLC purity >99% by reversed-phase chromatography. Below that band, walk away.

Mass-spec identity match to the calculated monoisotopic mass of the C187H291N45O59 sequence (~4,113 Da). A wrong mass means the molecule is not semaglutide.

Named third-party lab on the CoA - Janoshik Analytics and Freedom Diagnostics are the two most cited in the research-compound supply chain.

CoA published for the batch on sale.

Full walkthrough: How to Read a Certificate of Analysis.

Red flags on semaglutide listings

The semaglutide search surface is one of the most counterfeited in the entire peptide market. Walk away from any listing that:

Markets “Ozempic”, “Wegovy” or “Rybelsus” outside a licensed pharmacy. Those are Novo Nordisk trade names for the licensed medicine, not for research peptide.

Quotes dosing protocols, mg-per-week schedules, titration ladders or weight-loss promises . Those re-characterise the product as an unlicensed medicine.

Has no CoA , or shows a generic stock CoA with no batch number tied to your order.

Sells pre-filled pens or autoinjectors . Lyophilised reference peptide ships dry in a sealed vial. Pre-filled pens are medicine, not research compound.

Quotes a price implausibly far below the rest of the market.

Operates from a Telegram-only channel or a newly registered Shopify with no legal entity in the footer.

Storage & handling of lyophilised semaglutide

Lyophilised semaglutide is typically stored long-term at −20°C. Sealed vials tolerate brief shipping excursions. Warm vials to room temperature before opening to avoid condensation. After reconstitution, store at 2–8°C and protect from light. Use within a research-relevant window based on your stability data. Full reference: How to Store Peptides. For volume maths, use the reconstitution calculator.

Frequently Asked Questions

What is semaglutide? A 31-amino-acid synthetic peptide and a selective GLP-1 receptor agonist developed by Novo Nordisk. Approved as Ozempic (type-2 diabetes), Wegovy (chronic weight management) and Rybelsus (oral form).

How long is semaglutide’s half-life? Approximately 165 hours (~7 days) for the injectable form, supporting once-weekly dosing. Driven by a C18 fatty di-acid that reversibly binds albumin.

Is oral semaglutide the same molecule as injectable? Yes - Rybelsus is the same semaglutide molecule, co-formulated with the absorption enhancer SNAC to allow gastric uptake. Oral bioavailability is roughly 0.4–1.0%, which is why oral doses are an order of magnitude higher than injectable.

How is semaglutide different from tirzepatide? Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1 + GIP agonist. In SURMOUNT-5 (NEJM, 2025) tirzepatide produced a greater mean weight reduction over 72 weeks.

Is semaglutide a research compound on this site? Yes. New-U catalogues research-grade semaglutide as Semaglutide, lyophilised reference peptide with its Certificate of Analysis published online. Sold research use only.

Primary sources & further reading

New England Journal of Medicine - STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., 2021)

NEJM - SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (Lincoff et al., 2023)

Lancet Diabetes & Endocrinology - STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesity (Wharton et al., 2025; PMID 40961952)

Lancet Diabetes & Endocrinology - STEP UP T2D: Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (Lingvay et al., 2025; PMID 40961953)

NEJM - FLOW: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (Perkovic et al., 2024; PMID 38785209)

NEJM - ESSENCE: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (Sanyal et al., 2025; PMID 40305708)

NEJM - SOUL: Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (McGuire et al., 2025; PMID 40162642)

NEJM - SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (Aronne et al., 2025; PMID 40353578)

NEJM - OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (Wharton et al., 2025; PMID 40934115)

The Lancet - evoke and evoke+: Oral semaglutide in early-stage symptomatic Alzheimer’s disease (Cummings et al., 2026; PMID 41865758)

NIH/NCBI Bookshelf - StatPearls: Semaglutide

U.S. National Library of Medicine - PubMed: semaglutide

ClinicalTrials.gov - semaglutide trial registry

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way. Ozempic, Wegovy and Rybelsus are trade names of Novo Nordisk; New-U sells research-grade reference peptide only, not the licensed medicine.

From the Lab - Peptides on LinkedIn, TikTok & X

Lab-Verified Research Semaglutide

New-U Research Compounds catalogues semaglutide as Semaglutide - sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with the Certificate of Analysis for the tested sample published online. Tracked worldwide delivery. Research use only - all claims made on this site are for testing and research use only.

Research-grade · >99% HPLC purity · COA per lot

Buy Semaglutide from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research